These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 24128992)

  • 1. In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain.
    Bergeron M; Motter R; Tanaka P; Fauss D; Babcock M; Chiou SS; Nelson S; San Pablo F; Anderson JP
    Neuroscience; 2014 Jan; 256():72-82. PubMed ID: 24128992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of endogenous G-protein-coupled receptor kinases to Ser129 phosphorylation of alpha-synuclein in HEK293 cells.
    Sakamoto M; Arawaka S; Hara S; Sato H; Cui C; Machiya Y; Koyama S; Wada M; Kawanami T; Kurita K; Kato T
    Biochem Biophys Res Commun; 2009 Jul; 384(3):378-82. PubMed ID: 19410557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serine 129 phosphorylation of membrane-associated α-synuclein modulates dopamine transporter function in a G protein-coupled receptor kinase-dependent manner.
    Hara S; Arawaka S; Sato H; Machiya Y; Cui C; Sasaki A; Koyama S; Kato T
    Mol Biol Cell; 2013 Jun; 24(11):1649-60, S1-3. PubMed ID: 23576548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system.
    Inglis KJ; Chereau D; Brigham EF; Chiou SS; Schöbel S; Frigon NL; Yu M; Caccavello RJ; Nelson S; Motter R; Wright S; Chian D; Santiago P; Soriano F; Ramos C; Powell K; Goldstein JM; Babcock M; Yednock T; Bard F; Basi GS; Sham H; Chilcote TJ; McConlogue L; Griswold-Prenner I; Anderson JP
    J Biol Chem; 2009 Jan; 284(5):2598-2602. PubMed ID: 19004816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polo-like kinase 2 modulates α-synuclein protein levels by regulating its mRNA production.
    Kofoed RH; Zheng J; Ferreira N; Lykke-Andersen S; Salvi M; Betzer C; Reimer L; Jensen TH; Fog K; Jensen PH
    Neurobiol Dis; 2017 Oct; 106():49-62. PubMed ID: 28648742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age- and brain region-dependent α-synuclein oligomerization is attributed to alterations in intrinsic enzymes regulating α-synuclein phosphorylation in aging monkey brains.
    Chen M; Yang W; Li X; Li X; Wang P; Yue F; Yang H; Chan P; Yu S
    Oncotarget; 2016 Feb; 7(8):8466-80. PubMed ID: 27032368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ser129 phosphorylation of endogenous α-synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function.
    Buck K; Landeck N; Ulusoy A; Majbour NK; El-Agnaf OM; Kirik D
    Neurobiol Dis; 2015 Jun; 78():100-14. PubMed ID: 25818009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissecting the Molecular Pathway Involved in PLK2 Kinase-mediated α-Synuclein-selective Autophagic Degradation.
    Dahmene M; Bérard M; Oueslati A
    J Biol Chem; 2017 Mar; 292(9):3919-3928. PubMed ID: 28154193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. G protein-coupled receptor kinase 5, overexpressed in the alpha-synuclein up-regulation model of Parkinson's disease, regulates bcl-2 expression.
    Liu P; Wang X; Gao N; Zhu H; Dai X; Xu Y; Ma C; Huang L; Liu Y; Qin C
    Brain Res; 2010 Jan; 1307():134-41. PubMed ID: 19852948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polo-like kinase 2 inhibition reduces serine-129 phosphorylation of physiological nuclear alpha-synuclein but not of the aggregated alpha-synuclein.
    Elfarrash S; Jensen NM; Ferreira N; Schmidt SI; Gregersen E; Vestergaard MV; Nabavi S; Meyer M; Jensen PH
    PLoS One; 2021; 16(10):e0252635. PubMed ID: 34613964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S-Nitrosylation of G protein-coupled receptor kinase 6 and Casein kinase 2 alpha modulates their kinase activity toward alpha-synuclein phosphorylation in an animal model of Parkinson's disease.
    Wu W; Sung CC; Yu P; Li J; Chung KKK
    PLoS One; 2020; 15(4):e0232019. PubMed ID: 32343709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease.
    Sato H; Arawaka S; Hara S; Fukushima S; Koga K; Koyama S; Kato T
    J Neurosci; 2011 Nov; 31(46):16884-94. PubMed ID: 22090514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological inhibition of polo like kinase 2 (PLK2) does not cause chromosomal damage or result in the formation of micronuclei.
    Fitzgerald K; Bergeron M; Willits C; Bowers S; Aubele DL; Goldbach E; Tonn G; Ness D; Olaharski A
    Toxicol Appl Pharmacol; 2013 May; 269(1):1-7. PubMed ID: 23466428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylation of synucleins by members of the Polo-like kinase family.
    Mbefo MK; Paleologou KE; Boucharaba A; Oueslati A; Schell H; Fournier M; Olschewski D; Yin G; Zweckstetter M; Masliah E; Kahle PJ; Hirling H; Lashuel HA
    J Biol Chem; 2010 Jan; 285(4):2807-22. PubMed ID: 19889641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superiority of PLK-2 as α-synuclein phosphorylating agent relies on unique specificity determinants.
    Salvi M; Trashi E; Marin O; Negro A; Sarno S; Pinna LA
    Biochem Biophys Res Commun; 2012 Feb; 418(1):156-60. PubMed ID: 22248692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective and brain-permeable polo-like kinase-2 (Plk-2) inhibitors that reduce α-synuclein phosphorylation in rat brain.
    Aubele DL; Hom RK; Adler M; Galemmo RA; Bowers S; Truong AP; Pan H; Beroza P; Neitz RJ; Yao N; Lin M; Tonn G; Zhang H; Bova MP; Ren Z; Tam D; Ruslim L; Baker J; Diep L; Fitzgerald K; Hoffman J; Motter R; Fauss D; Tanaka P; Dappen M; Jagodzinski J; Chan W; Konradi AW; Latimer L; Zhu YL; Sham HL; Anderson JP; Bergeron M; Artis DR
    ChemMedChem; 2013 Aug; 8(8):1295-313. PubMed ID: 23794260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease.
    Braithwaite SP; Stock JB; Mouradian MM
    Rev Neurosci; 2012 Mar; 23(2):191-8. PubMed ID: 22499677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models.
    Sato H; Kato T; Arawaka S
    Rev Neurosci; 2013; 24(2):115-23. PubMed ID: 23314528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin Resistance Promotes Parkinson's Disease through Aberrant Expression of α-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling.
    Hong CT; Chen KY; Wang W; Chiu JY; Wu D; Chao TY; Hu CJ; Chau KD; Bamodu OA
    Cells; 2020 Mar; 9(3):. PubMed ID: 32192190
    [No Abstract]   [Full Text] [Related]  

  • 20. Iron-induced oxidative stress contributes to α-synuclein phosphorylation and up-regulation via polo-like kinase 2 and casein kinase 2.
    Wang R; Wang Y; Qu L; Chen B; Jiang H; Song N; Xie J
    Neurochem Int; 2019 May; 125():127-135. PubMed ID: 30797969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.